Improving global healthcare access thanks to a continuous and sustainable mRNA manufacturing solution.
Dillico was cofounded by senior industry experts for the purpose of developing and marketing a unique integrated and digitalized all-scale-range mRNA drug product manufacturing solution.
With its continuous and automated mRNA-LNP manufacturing system, Dillico is revolutionizing the landscape of the biopharma industry.
Our proprietary flow technology and unique production process allow for the production of mRNA vaccines and therapies at any scale, from discovery to commercial manufacturing, using the same piece of equipment. This continuous all-scale solution significantly reduces the time and effort that goes into development, as well as offering unmatched flexibility in terms of production capacity.
TEAM

Christophe Bonneville
CEO & co-founder
Christophe Bonneville leads the company’s global strategy with a vision that champions the adoption of Pharma 4.0 solutions on the global pharma market. Previously, he was co-founder and CEO of Resolution Spectra, which was acquired by Merck Millipore in 2020 for its bioprocess monitoring solution. He has also held Business Unit Manager and Program Manager roles at various companies in the space industry. He holds a PhD in Physics, specifically in the field of Instrumental Optics, and is a graduate of Ecole Centrale de Marseille in France.

Flora Binder
Chief Development Officer & co-founder
Flora leads the process development of Dillico’s technology to provide robust, fully digitized and optimized manufacturing solutions. Previously, she has been working at Moderna and Biogen in Manufacturing Science, she was responsible for process technology transfer and validation activities. She received her Masters Degree in Biotechnology from Grenoble Alpes University.

Emmanuel Gaud
Chief Operating officer & co-founder
Emmanuel Gaud acts as a Chief Operating Officer. After completion of AgroParis Tech School, Emmanuel has been working with passion in the Life Science Industries. For 23 years, he has built process system design addressing the food, cosmetics, pharmaceutical and biotech market. Emmanuel is now putting his strength working with Dillico to bring to life the manufacturing solution.

Daniel Marquez Martin
Process Scientist

Jean de Seze
Development Scientist

Lucas Audoui
Senior Process Equipment Engineer

Brice Pawelec
Process Engineer
Strategic Board

Flora Binder
Co-founder & Observer

Christophe Bonneville
Co-founding CEO & Chairperson

Marie Chambobut
Board Member

Eva Clerc
Board Member

Emmanuel Gaud
Co-founder & Observer

Maximilien Glenat
Board Member

Guillaume Leroy
Board Member
NEWS
Dillico announces the closing of a €7.5 million financing round to launch the commercialization of its innovative solution for the manufacturing of messenger RNA vaccines and therapies
Meylan, France, July 9, 2025 - Dillico announces the completion of a financing round with Angelor, the Fonds Régional Avenir Industrie of the Auvergne-Rhône-Alpes Region (advised by UI Investissement), the French Tech [...]
Join our Team – Our Offers
Want to join our team ? May be an opportunity for you: mRNA-LNP Senior Process Development Scientist Biochemistry Lab Technician Product Marketing Manager – Biopharma Manufacturing Solutions Responsable Administratif et Financier Biotech/Pharma [...]
National Day of Biomedicine Bioproduction – June 5, 2025.
National Day of Biomedicine Bioproduction – June 5, 2025. Physical and digital events across France to help you discover this essential link in the healthcare of tomorrow. The National Day of Bioproduction [...]
Dillico at the 3rd mRNA Process Development & Manufacturing Summit | September 17-19 | Boston, MA, USA
Dillico attended to the 3rd mRNA Process Development & Manufacturing Summit in Boston this September 17-19. Our CEO, Christophe BONNEVILLE, talked about the development of a Continuous Manufacturing Solution for All-Scale mRNA-LNP [...]
Dillico celebrates a major milestone | September 6 | Meylan, France
On Friday the 6th of September, Dillico celebrated with our partners and ecosystem a major milestone: the inauguration of our new labs and the presentation of our finalized automatized continuous In Vitro [...]
Dillico to present All-ScaleFlow Technology at MSS2024 Symposium | June 3-7 | Portoroz, Slovenia
Our Chief Development Officer Flora Binder will present our All-scale continuous mRNA-LNP manufacturing technology at MSS2024 | June 3-7 | Portoroz, Slovenia. This hybrid event organized by Sartorius BIA Separations will feature [...]
Dillico reveals the design of its continuous manufacturing process equipment for mRNA therapies and vaccines
Dillico reveals the design of its continuous manufacturing process equipment for mRNA therapies and vaccines on its new website’s version. The 3D on display gives a great insight into the level of [...]
Dillico moved
We are thrilled to announce that we are transitioning our site to a new location. As of now, we'll be located at Inovallée, Meylan; near our previous office in Grenoble. We’re heading [...]
All-ScaleFlow™ Technology Presentation at Bioproduction Congress Lyon
The mRNA Revolution: During the pandemic, the implementation of mRNA technology was carried out at a record pace, utilizing existing manufacturing solutions developed for conventional vaccines. However, this approach came with its [...]
Dillico Grand Prix i-Lab 2023
Dillico Grand Prix i-Lab 2023 (English version below) Nous sommes honorés d'avoir été choisis parmi de nombreux candidats exceptionnels, comme lauréat du Grand prix i-Lab 2023 ! Ce prix revêt une importance particulière [...]
Afrigen Biologics and Dillico sign CRADA to advance mRNA manufacturing solutions
Afrigen Biologics, the development lead in the mRNA technology transfer programme and Dillico Announce Cooperative R&D Agreement to test a new continuous mRNA Manufacturing Solution adapted for low- and middle-income countries. Cape [...]
Flora Binder to join Dillico as Chief Development Officer
We are pleased to announce today that Flora Binder has taken up her role of Dillico’s Chief Development Officer. “Flora has a solid expertise in mRNA process transfer in the global pharmaceutical industry and it will be a significant asset to Dillico to advance [...]
French Tech Emergence Grant for Dillico
Dillico is pleased to announce that it has been awarded a French Tech Emergence grant by BPIFrance, which we thank. This financial support is granted to startup projects that develop a disruptive [...]
PARTNERS